Expertise in
7
conditions

Takako E. Nakajima

Kyoto, JP 
Expertise in
7
conditions
Kyoto, JP 

Overview

Takako Nakajima practices practicing medicine in Kyoto, Japan.

Ms. Nakajima is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Stomach Cancer, Colorectal Cancer, Periodontitis, Endoscopy, and Hepato-Pancreato-Biliary Surgery.

She is actively involved in clinical research, co-authoring 109 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Kyoto, Japan
Other Locations
Kawahara, 6068507, Japan
Nakajima, Japan
Kawahara, 6068507, Japan
Matsumoto, 3908621, Japan
Funabashi, Japan
Okayama, 7168508, Japan
Osaka, Japan
St. Marianna University School of Medical Hospital
Kanagawa, 2168511, Japan
Chuo, 9518514, Japan
St. Marianna University School of Medicine
Kawasaki, Japan
St. Marianna University School of Medicine Hospital
Japan
Tokyo, Japan
Niigata, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase I, Open Label, Dose Escalation Study of The Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as A Single Agent to Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase I, Open Label, Dose Escalation Study of The Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as A Single Agent to Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Drug
Study Phase: Phase 1

109 Total Publications

Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 15, 2026

Frequently Asked Questions about Takako E. Nakajima

Is Takako E. Nakajima a top-rated expert for Stomach Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Takako E. Nakajima is classified as an Elite expert for Stomach Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Takako E. Nakajima participate in research or clinical trials?

Yes. Takako E. Nakajima has published 109 articles and abstracts on conditions like Stomach Cancer. You can view a list of Takako E. Nakajima's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Nakajima's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile